{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:53:23Z","timestamp":1790636003363,"version":"4.1.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Univerzita Palack\u00e9ho v Olomouci","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.blre.2021.100824","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T01:06:45Z","timestamp":1615511205000},"page":"100824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Revisiting Richter transformation in the era of novel CLL agents"],"prefix":"10.1016","volume":"49","author":[{"given":"Anna","family":"Petrackova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Turcsanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Papajik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kriegova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100824_bb0005","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"issue":"4","key":"10.1016\/j.blre.2021.100824_bb0010","first-page":"285","article-title":"Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia","volume":"4","author":"Richter","year":"1928","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2021.100824_bb0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/asheducation-2018.1.256","article-title":"Richter transformation in the era of novel agents","volume":"2018","author":"Ding","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.blre.2021.100824_bb0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11899-014-0223-4","article-title":"Risk factors for Richter syndrome in chronic lymphocytic leukemia","volume":"9","author":"Parikh","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.2011.08907.x","article-title":"Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature","volume":"156","author":"Bockorny","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2021.100824_bb0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0002-9343(80)90300-9","article-title":"Richter\u2019s syndrome: diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. A report of five cases and review of the literature","volume":"68","author":"Trump","year":"1980","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0035","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1309\/AJCPWQ0I0DGXBMHO","article-title":"Transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone","volume":"132","author":"Fraser","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1016\/j.blre.2021.100824_bb0040","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/modpathol.2011.102","article-title":"Clonally related histiocytic\/dendritic cell sarcoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: a study of seven cases","volume":"24","author":"Shao","year":"2011","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1309\/AJCPXE5VMONMVLZ0","article-title":"B-lymphoblastic leukemia in patients with chronic lymphocytic leukemia: a report of four cases","volume":"144","author":"Chakhachiro","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"10.1016\/j.blre.2021.100824_bb0050","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2016.02.012","article-title":"Richter syndrome: pathogenesis and management","volume":"43","author":"Rossi","year":"2016","journal-title":"Semin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2021.100824_bb0060","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100824_bb0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","article-title":"Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion","volume":"55","author":"Xiao","year":"2016","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.blre.2021.100824_bb0070","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.14700","article-title":"An update for Richter syndrome - new directions and developments","volume":"178","author":"Eyre","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2021.100824_bb0075","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"issue":"25","key":"10.1016\/j.blre.2021.100824_bb0080","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2021.100824_bb0085","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.23939","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma","volume":"90","author":"Parikh","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-017-3149-9","article-title":"Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies","volume":"97","author":"Khan","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0095","first-page":"348","article-title":"Richter transformation of chronic lymphocytic leukemia in the era of novel agents","volume":"18","author":"Wang","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0100","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is highly expressed by neoplastic B-cells in Richter transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2021.100824_bb0105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 expression in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) and large B-cell Richter Transformation (DLBCL-RT): A characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.blre.2021.100824_bb0110","first-page":"1267","article-title":"Detection of Richter\u2019s transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0115","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2015.21","article-title":"Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease","volume":"29","author":"Mauro","year":"2015","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.blre.2021.100824_bb0120","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0125","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","article-title":"An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter\u2019s Syndrome","volume":"57","author":"Michallet","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"S1","key":"10.1016\/j.blre.2021.100824_bb0130","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.V130.Suppl_1.834.834","article-title":"Analysis of PET-CT to identify Richter\u2019s transformation in 167 patients with disease progression following kinase inhibitor therapy","volume":"130","author":"Mato","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2021.100824_bb0135","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1993.11.10.1985","article-title":"Richter\u2019s syndrome: a report on 39 patients","volume":"11","author":"Robertson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0140","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/1097-0142(19810915)48:6<1302::AID-CNCR2820480609>3.0.CO;2-Q","article-title":"Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter\u2019s syndrome: A study of 25 cases","volume":"48","author":"Harousseau","year":"1981","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.blre.2021.100824_bb0145","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0150","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1211::AID-CNCR21>3.0.CO;2-1","article-title":"Hypercalcemia may indicate Richter\u2019s syndrome: report of four cases and review","volume":"79","author":"Beaudreuil","year":"1997","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000455913","article-title":"Richter\u2019s syndrome with hypercalcemia induced by tumor-associated production of parathyroid hormone-related peptide","volume":"10","author":"Watanabe","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0160","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/10428194.2013.802313","article-title":"Kapit\u00e1\u0148ov\u00e1, Proch\u00e1zka V, et al. 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","volume":"55","author":"Papaj\u00edk","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100824_bb0165","article-title":"The role of 18F-FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0175","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.blre.2021.100824_bb0180","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients With chronic lymphocytic leukemia with 17p deletion: results from the full population of a Phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.blre.2021.100824_bb0185","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood."},{"issue":"S1","key":"10.1016\/j.blre.2021.100824_bb0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.2222","article-title":"XIV. The pathology of transformation of indolent B cell lymphomas: transformation low-grade lymphoma","volume":"33","author":"Gascoyne","year":"2015","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.blre.2021.100824_bb0195","first-page":"86","article-title":"Prolymphocytic and Richter\u2019s transformation in peripheral blood: A case report and review of literature","volume":"3","author":"Rana","year":"2014","journal-title":"J Hematol"},{"issue":"22","key":"10.1016\/j.blre.2021.100824_bb0200","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1182\/blood-2009-06-192153","article-title":"Richter transformation in peripheral blood","volume":"115","author":"Hamilton","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2021.100824_bb0205","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1007\/s00330-019-06291-9","article-title":"Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of richter syndrome","volume":"29","author":"Reinert","year":"2019","journal-title":"Eur Radiol"},{"issue":"10","key":"10.1016\/j.blre.2021.100824_bb0210","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00277-018-3390-x","article-title":"Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales","volume":"97","author":"Federmann","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0215","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/his.13024","article-title":"Diagnostic dilemmas of high-grade transformation (Richter\u2019s syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review","volume":"69","author":"Soilleux","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.blre.2021.100824_bb0220","series-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.blre.2021.100824_bb0225","series-title":"Diagnostic pathology: lymph nodes and spleen with extranodal lymphomas","author":"Medeiros","year":"2011"},{"issue":"10","key":"10.1016\/j.blre.2021.100824_bb0230","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter\u02bcs transformation: diffuse large B-cell lymphoma and hodgkin lymphoma in association with B-cell Chronic Lymphocytic Leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.blre.2021.100824_bb0235","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ajh.24473","article-title":"Histologic transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"91","author":"Agbay","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2021.100824_bb0240","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/leu.2011.247","article-title":"Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays","volume":"26","author":"Ciccone","year":"2012","journal-title":"Leukemia"},{"issue":"S1","key":"10.1016\/j.blre.2021.100824_bb0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2399","article-title":"The 2016 updated WHO classification of lymphoid neoplasias","volume":"35","author":"Quintanilla-Martinez","year":"2017","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.blre.2021.100824_bb0250","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/00000478-200405000-00018","article-title":"Distinct clonal origin in two cases of Hodgkin\u2019s lymphoma variant of Richter\u2019s syndrome associated with EBV infection","volume":"28","author":"de Leval","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0255","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2021.100824_bb0260","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gin\u00e9","year":"2010","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2021.100824_bb0265","first-page":"902","article-title":"Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity","volume":"6","author":"Cordone","year":"1992","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2021.100824_bb0270","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023566","article-title":"Risk factors associated with Richter\u2019s transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study","volume":"9","author":"Hleuhel","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0275","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0280","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","article-title":"Richter\u2019s transformation in patients with chronic lymphocytic leukaemia: a nationwide epidemiological study","volume":"61","author":"Ben-Dali","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100824_bb0285","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100824_bb0290","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2018-04-845115","article-title":"MiR-125a and MiR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients","volume":"132","author":"Balatti","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100824_bb0295","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.2018.203828","article-title":"The involvement of microRNA in the pathogenesis of Richter syndrome","volume":"104","author":"Van Roosbroeck","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2021.100824_bb0300","doi-asserted-by":"crossref","first-page":"IJH09","DOI":"10.2217\/ijh-2018-0010","article-title":"Current trends in the management of Richter\u2019s syndrome","volume":"7","author":"Allan","year":"2019","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.blre.2021.100824_bb0305","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2008.399","article-title":"Telomere length is an independent predictor of survival, treatment requirement and Richter\u2019s syndrome transformation in chronic lymphocytic leukemia","volume":"23","author":"Rossi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2021.100824_bb0310","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"224121","author":"Wang","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2021.100824_bb0315","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clml.2015.02.001","article-title":"Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia","volume":"15","author":"Strati","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2021.100824_bb0320","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2021.100824_bb0325","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2010.08482.x","article-title":"Avariant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"152","author":"Rasi","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0330","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2141.2005.05426.x","article-title":"Hodgkin\u2019s disease variant of Richter\u2019s syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine","volume":"129","author":"Fong","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100824_bb0335","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jclinpath-2018-205622","article-title":"Relevance of TP53 for CLL diagnostics","volume":"72","author":"Catherwood","year":"2019","journal-title":"J Clin Pathol"},{"issue":"29","key":"10.1016\/j.blre.2021.100824_bb0340","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100824_bb0345","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial","volume":"29","author":"Gonzalez","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6456","key":"10.1016\/j.blre.2021.100824_bb0350","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/366704a0","article-title":"A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4","volume":"366","author":"Serrano","year":"1993","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.blre.2021.100824_bb0355","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/0008-5472.CAN-07-0426","article-title":"Myc goes global: new tricks for an old oncogene","volume":"67","author":"Knoepfler","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2021.100824_bb0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","article-title":"The c-Myc target gene network","volume":"16","author":"Dang","year":"2006","journal-title":"Semin Cancer Biol"},{"issue":"24","key":"10.1016\/j.blre.2021.100824_bb0365","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","article-title":"High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations","volume":"120","author":"Edelmann","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2021.100824_bb0370","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3109\/10428194.2012.723706","article-title":"MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia","volume":"54","author":"De Paoli","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2021.100824_bb0375","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0380","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2011-10-386144","article-title":"NOTCH1 mutations in CLL associated with trisomy 12","volume":"119","author":"Balatti","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2021.100824_bb0385","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2011.060129","article-title":"NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL","volume":"97","author":"Del Giudice","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2021.100824_bb0390","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical Notch signaling pathway: unfolding the activation mechanism","volume":"137","author":"Kopan","year":"2009","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.blre.2021.100824_bb0395","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrg3272","article-title":"The Notch signalling system: recent insights into the complexity of a conserved pathway","volume":"13","author":"Guruharsha","year":"2012","journal-title":"Nat Rev Genet"},{"issue":"14","key":"10.1016\/j.blre.2021.100824_bb0400","doi-asserted-by":"crossref","first-page":"E2911","DOI":"10.1073\/pnas.1702564114","article-title":"Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia","volume":"114","author":"Fabbri","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2021.100824_bb0405","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2141.2009.07816.x","article-title":"A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation","volume":"146","author":"Di Ianni","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100824_bb0410","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0415","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2021.100824_bb0420","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2021.100824_bb0425","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100824_bb0430","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.blre.2021.100824_bb0435","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2021.100824_bb0440","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0445","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.3324\/haematol.2018.202085","article-title":"Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia","volume":"104","author":"Kiss","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0450","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"S1","key":"10.1016\/j.blre.2021.100824_bb0455","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/blood-2019-128425","article-title":"A CRISPR\/Cas9-generated murine model reveals cooperation between BCR signaling and CDKN2A\/2B and TP53 disruption in Richter Syndrome","volume":"134","author":"Chakraborty","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2021.100824_bb0460","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100824_bb0465","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2021.100824_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00894","article-title":"Resistance-associated mutations in chronic lymphocytic leukaemia patients treated with novel agents","author":"Sedlarikova","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.blre.2021.100824_bb0475","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"10.1016\/j.blre.2021.100824_bb0480","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0485","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jmoldx.2017.11.006","article-title":"MYD88 mutations and sensitivity to ibrutinib therapy","volume":"20","author":"Wang","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.blre.2021.100824_bb0490","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fonc.2018.00229","article-title":"NOTCH1 aberrations in chronic lymphocytic leukemia","volume":"8","author":"Rosati","year":"2018","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.blre.2021.100824_bb0495","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100824_bb0500","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fonc.2019.00851","article-title":"Standardization of sequencing coverage depth in NGS: recommendation for detection of Clonal and subclonal mutations in cancer diagnostics","volume":"9","author":"Petrackova","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2021.100824_bb0505","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1038\/ncomms14756","article-title":"Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.blre.2021.100824_bb0510","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2017-03-735639","article-title":"High-throughput sequencing for noninvasive disease detection in hematologic malignancies","volume":"130","author":"Scherer","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2021.100824_bb0515","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0520","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/genetics\/156.1.297","article-title":"Estimate of the mutation rate per nucleotide in humans","volume":"156","author":"Nachman","year":"2000","journal-title":"Genetics"},{"issue":"11","key":"10.1016\/j.blre.2021.100824_bb0525","doi-asserted-by":"crossref","first-page":"233","DOI":"10.21037\/atm.2018.05.22","article-title":"Noninvasive cancer biomarkers in solid malignancies: circulating tumor DNA-clinical utility, current limitations and future perspectives","volume":"6","author":"de Melo","year":"2018","journal-title":"Ann Transl Med"},{"issue":"13","key":"10.1016\/j.blre.2021.100824_bb0530","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2021.100824_bb0535","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3109\/10428194.2012.664845","article-title":"Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia","volume":"53","author":"Fan","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"9583","key":"10.1016\/j.blre.2021.100824_bb0540","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0545","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"S15","key":"10.1016\/j.blre.2021.100824_bb0550","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2017.35.15_suppl.7505","article-title":"Richter\u2019s syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2021.100824_bb0555","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (Daunoxome), and dexamethasone (HyperCVXD) regimen in Richter\u2019s syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0560","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter\u2019s syndrome: results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2021.100824_bb0565","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0570","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter\u2019s Syndrome or Fludarabine-Refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2021.100824_bb0575","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0580","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2021.100824_bb0585","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2021.100824_bb0590","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.22121","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2021.100824_bb0595","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL) -a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","author":"Al-Sawaf","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2021.100824_bb0600","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0605","first-page":"785","article-title":"Hodgkin\u2019s variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group","volume":"34","author":"Tadmor","year":"2014","journal-title":"Anticancer Res"},{"issue":"15S","key":"10.1016\/j.blre.2021.100824_bb0610","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2020.38.15_suppl.8004","article-title":"Montegaard, et al. A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter\u2019s syndrome","volume":"38","author":"Davids","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2021.100824_bb0615","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0620","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bjh.15440","article-title":"BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome","volume":"185","author":"Visentin","year":"2019","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.blre.2021.100824_bb0625","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood.V128.22.60.60","article-title":"Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1\/2 ACE-CL-001 Clinical Study","volume":"128","author":"Hillmen","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0630","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"issue":"S2","key":"10.1016\/j.blre.2021.100824_bb0635","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/hon.79_2629","article-title":"Phase I\/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with REL\/REF CLL and Richter\u2019s transformation","volume":"37","author":"Mato","year":"2019","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0640","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1016\/j.blre.2021.100824_bb0645","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V128.22.59.59","article-title":"Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial","volume":"128","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100824_bb0650","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hon.4_2632","article-title":"A multicentre, open label, uncontrolled, phase II trial evaluating safety and efficacy of venetoclax, atezolizumab and obinutuzumab in Richter transformation from CLL","volume":"37","author":"Montillo","year":"2019","journal-title":"Hematol Oncol"},{"issue":"24","key":"10.1016\/j.blre.2021.100824_bb0655","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0660","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/10428194.2018.1461862","article-title":"Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome","volume":"60","author":"Alderuccio","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"S1","key":"10.1016\/j.blre.2021.100824_bb0665","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood-2019-128564","article-title":"Preliminary safety and anti-tumor activity of XmAb13676, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2021.100824_bb0670","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100824_bb0675","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-Cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an Anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2021.100824_bb0680","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen Receptor\u2013modified t cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100824_bb0685","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-99-111061","article-title":"Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-Cells alone or in combination with ibrutinib for relapsed and\/or refractory CLL","volume":"132","author":"Gauthier","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0690","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s40425-019-0686-x","article-title":"State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019","volume":"7","author":"Lemal","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"18","key":"10.1016\/j.blre.2021.100824_bb0695","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0700","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.blre.2021.100824_bb0705","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.blre.2021.100824_bb0710","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100824_bb0715","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2021.100824_bb0720","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ajh.25436","article-title":"Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis","volume":"94","author":"O\u2019Brien","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.blre.2021.100824_bb0725","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1080\/10428194.2019.1620944","article-title":"Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece","volume":"60","author":"Dimou","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0730","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.blre.2021.100824_bb0735","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0740","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2021.100824_bb0745","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"UK CLL Forum","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2021.100824_bb0750","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O\u2019Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"S1","key":"10.1016\/j.blre.2021.100824_bb0755","first-page":"498","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated results from the phase 1\/2 ACE-CL-001 study","volume":"130","author":"Byrd","year":"2017","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2021.100824_bb0760","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/cam4.1337","article-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study","volume":"7","author":"Huang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2021.100824_bb0765","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/JBM.S202286","article-title":"Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis","volume":"10","author":"Nuttall","year":"2019","journal-title":"J Blood Med"},{"issue":"19","key":"10.1016\/j.blre.2021.100824_bb0770","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2021.100824_bb0775","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.3324\/haematol.2018.198820","article-title":"Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort","volume":"104","author":"Winqvist","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2021.100824_bb0780","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100824_bb0785","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.blre.2021.100824_bb0790","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia","volume":"126","author":"O\u2019Brien","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2021.100824_bb0795","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2021.100824_bb0800","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.blre.2021.100824_bb0805","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2021.100824_bb0810","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1470-2045(18)30414-5","article-title":"Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Cramer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.blre.2021.100824_bb0815","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2019-01-896290","article-title":"Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed\/refractory chronic lymphocytic leukemia","volume":"133","author":"Flinn","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2021.100824_bb0820","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2021.100824_bb0825","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2021.100824_bb0830","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.blre.2021.100824_bb0835","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2021.100824_bb0840","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2018-05-853564","article-title":"Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia","volume":"132","author":"Rogers","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2021.100824_bb0845","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/bjh.15802","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis","volume":"185","author":"Eyre","year":"2019","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.blre.2021.100824_bb0850","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1158\/1078-0432.CCR-19-0361","article-title":"Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice","volume":"25","author":"Roeker","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.blre.2021.100824_bb0855","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1172\/JCI64101","article-title":"Molecular pathogenesis of chronic lymphocytic leukemia","volume":"122","author":"Gaidano","year":"2012","journal-title":"J Clin Invest"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:25:29Z","timestamp":1759436729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":171,"alternative-id":["S0268960X21000308"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100824","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting Richter transformation in the era of novel CLL agents","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100824"}}